Introduction
It has been obvious since the very early days of steroid therapy for allergic asthma that the deposition of the active drug directly on to the bronchial mucosa by means of an aerosol could be an advantageous method of treatment. The drug would be-delivered only at the site where it was required. The local concentration could be high, yet systemic absorption minimal and the side effects of steroid therapy avoided.
Attempts to establish this method have been the subject of reports by many investigators from Gelfand (1951) onwards, including studies by Brockbank et al. (1956) , Brockbank and Pengelly (1958) , Helm and Heyworth (1958) , Herxheimer et al (1958) , Smith (1958) , Bickerman and Itkin (1963) , Brown (1963) , and a further publication, including a review of nine others, by Kravis and Lecks (1966 Siegel et al. (1964) , Novey and Beall (1965) , and Toogood and Lefcoe (1965) . Biochemical evidence of adrenal suppression was reported by Linder (1964) . Systemic absorption of dexamethasone thus proved an insuperable problem which rendered administration of this steroid by aerosol rather pointless.
Beclomethasone dipropionate, which has already been used for some years as a topical ointment for eczema, does not suffer from this defect. This compound was used in aerosol form for the present trial.
Case Selection Sixty patients were selected for the trial from both National Health Service and private practices. All except one were stable perennial asthmatics, as shown by observation over a period of from six months to 16 years. Sputum examination in 59 cases showed a significant excess of eosinophil cells. Intensive investigation of allergic factors and treatment, when indicated, using the methods described by Brown (1970) had been ineffective or unhelpful. Thirty-seven of the patients had been continuously dependent on steroid therapy for from 1 to 16 years, taking total daily doses of from 0 5 to 1-5 mg of betamethasone or 5 to 15 mg of prednisolone. Repeated attempts at steroid withdrawal had resulted in relapse. Thirty-five of the steroiddependent group had previously taken part in a trial (unpublished) of disodium cromoglycate but only four had improved.
The cases were not classified as intrinsic or extrinsic, but simply as perennial allergic asthma. The extent of the reversibility of the airways obstruction in each case varied widely, and steroid-dependent patients were well indoctrinated to take the minimum dose possible. As shown in Table I known not to respond to doses of 200 units of corticotrophin gel because of adrenal suppression. They were considered almost certainly steroid-dependent for life and this fact influenced their selection for a trial of a new mode of treatment. The patients were therefore a miscellaneous group of proved allergic asthmatics. In 37 there was serious anxiety regarding their future because of dependence on steroid therapy and in 23 control by bronchodilators was regarded as inadequate and steroid therapy was considered inadvisable on a long-term basis.
The importance of sputum eination for eosinophils was brought home to us by the patient (Case 60) who did not have this investigation before entry to the trial. He was a 36-year-old ex-marine commando who gave a history so suggestive of mild allergic asthma of several years' duration that a search for causative allergens lasted over six months. It was then decided to give up attempts to find a cause and, as he was already using a peak flow meter, he was given the aerosol steroid. Two weeks later one of us (H. M. B.) was surprised to find that the expected increase in peak flow had not occurred. The sputum was belatedly examined and the cytological examination showed typical bronchitis with no eosinophils. The true diagnosis was, of course, early chronic bronchitis.
This case illustrates the value of examination of the sputum for eosinophils, so long as the methods described by Brown (1958) are strictly adhered to. It must be emphasized that the routine laboratory examination for eosinophils is not worth while unless the technician has been shown the simple method described. Two puffs four times daily, giving a total of 400 tug, was the usual dose, occasionally increased to three puffs four times a day. In 56 cases 400~tg was the optimum dose but four remained well controlled on 150 to 200 t.g daily. This dosage regimen is empirical, and may not be optimal. Three patients changed to 200 Fg twice a day and had a gradual decrease in peak flow rate, suggesting that it is best to use the aerosol at least four times daily.
Material and Methods
Most of the patients had used pressurized aerosols for long periods. Nevertheless, it was felt necessary to give practical instruction on their use before beginning the trial. Particular emphasis was placed on preliminary complete expiration and on firing the aerosol at the very beginning of inspiration, ensuring that particles of steroid are carried on the airstream as far down the bronchi as possible. It soon became obvious that many patients had never been instructed properly.
Each patient was supplied with a Wright Peak Flow Meter for personal use four times a day, fully instructed in its use, and shown how to keep a graph of the results. In addition, a very comprehensive symptoms diary was kept which included a daily record of all types of therapy. This is shown in Fig. 1 period of at least two weeks preceded the introduction of the aerosol. Many patients had already been keeping peak flow records for long periods as part of an intensive investigation. When the patient was seen again, if record-keeping was good aerosol therapy was started, but if record-keeping was inadequate the case was rejected as unsuitable.
In steroid-dependent patients the aerosol, 100 jig four times a day, was added to the usual daily dose of oral steroids for four days, after which the oral steroid was gradually phased out over the next three to four days. For example, a patient taking 10 mg of prednisolone daily would reduce the dose by 2-5 mg/day, or if on betamethasone 1 mg daily, by 0-25 mg/day.
Peak flow readings were averaged over at least two weeks before the aerosol was introduced, readings over periods of many months being available in those patients who were being studied intensively. The average readings after the introduction of the aerosol were taken from a two-week period beginning from two weeks after the transfer to the aerosol or from the point at which the peak flow rate had become stabilized.
Results STEROID-DEPENDENT GROUP (37 CASES) These 37 cases are summarized in Fig. 2 and Table I , which also shows the "side effects" encountered in introducing the aerosol. Seventeen steroid-dependent patients experienced withdrawal symptoms to a greater or lesser degree. These consisted of tiredness, lassitude, headache, aches and pains, depression, and occasionally emotional instability, lasting for a week or longer. All but three were already known not to respond to cortico- This surprising finding suggests that lack of exogenous oral corticosteroid in the blood stream, contrasting with local suppression of the bronchial allergy, had unmasked latent allergic symptoms in the nasal mucosa or skin. This finding contrasts markedly with the reports of Novey and Beall (1965) and of Toogood and Lefcoe (1965) , who observed (and photographed) pronounced Cushingoid effects from dexamethasone phosphate aerosols. Moonface became less evident in those in whom this side effect was prominent. One patient who had been on steroids for 10 years was delighted by the fact that many of her friends failed to recognize her in the street. On their own these effects suggest that systemic absorption of the steroid is negligible, quite apart from the results of tetracosactrin and insulin tests shown in Fig. 3 (Cases 6, 9, 11, 21, and 28) did not show objective improvement on aerosol, but the fact that they became independent of oral steroids was regarded as most gratifying and they were considered successful transfers.
STEROID-INDEPENDENT GROUP (23 CASES)
There were seldom difficulties in establishing these patients on the aerosol, except in the failures. The results are shown in Table II Nairn and McNeil (1963) . Note the effects of the aerosol on the peak expiratory flow which soon becomes almost equal to the peak inspiratory flow. peak inspiratory and expiratory flow, using a meter modified according to Nairn and McNeill (1963) , and also vital capacity, using a Wright Respirometer, were obtained, thanks to the very high'degree of co-operation from his mother. In order to obtain further evidence regarding possible adrenal suppression three volunteer subjects inhaled excessive quantities of the aerosol daily for two days, following several daily basal cortisol estimations. The results are shown in Fig. 9 , and from this it is clear that in at least three subjects there is no evidence whatever of the occurrence of adrenal suppression in higher dosages than have been used normally in the treatment of patients.
Conclusions and Discussion
Beclomethasone dipropionate aerosol would seem to provide an alternative to long-term oral steroid therapy in many cases of chronic perennial asthma. Effective control of the asthma is achieved with no evidence of systemic absorption or of steroid side effects. The exact mode ofaction ofthis compound remains to be fully elucidated.
The best results are in the younger and more reversible cases. The abolition of diurnal fluctuation is a surprising feature. It is possible to substitute this therapy for long-term oral steroids even when taken for many years. Steroid withdrawal symptoms, and unmasking of hitherto suppressed allergic manifestations, have presented interesting problems.
Selection of pure allergic asthmatics, or cases where the allergic factor is dominant, is a sine qua non of this, or any other, trial of a steroid preparation in allergic asthma Care has been taken to exclude seasonal cases, where daily fluctuations of airborne allergens can cause wide variation in peak flow.
It cannot be overemphasized that these patients are in a precarious condition in the event of trauma or infection. It is essential that they be instructed to resume oral steroids in high dosage without delay, when obviously necessary, without waiting for medical advice. They must carry warning cards clearly indicating their potentially dangerous situation.
Such serious problems do not arise in relation to patients who have had only occasional steroid therapy, or have never required it. On the data presented here there seems to be no contraindication to the use of this preparation by mild asthmatics who would not normally be considered for the use of corticosteroids. As many of them had already failed to respond to disodium cromoglycate this new therapeutic approach may have much to offer, especially in paediatrics. In all types of case considerable clinical expertize and experience of the management of allergic asthma may be required during the transfer period.
This method of treatment has no place whatever in status asthmaticus. Those unable to inhale air surely cannot inhale enough aerosol to have any effect. The presence of excess bronchial mucus and often pus must also form a barrier the aerosol cannot penetrate. The future role of aerosol therapy is clearly confined to maintenance of airway patency and prevention of attacks.
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